| Species |
Human |
| Protein Construction |
LIF (Ser23-Phe202)
Accession # P15018-1 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 0.1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized LIF, Human at 2μg/ml (100μl/Well) on the plate can bind Human LIF R, hFc Tag. Test result was comparable to standard batch.
Determined by its dosedependent ability to induce reporter gene in 293TSTAT3Luc2 reporter cells. The ED50 for this effect is 15 ng/mL. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
19.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-55 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Leukemia inhibitory factor (LIF) has played a vital role in a series of reproductive events, including follicle growth, embryo growth and differentiation. However, it is unclear whether the level of LIF in embryo culture medium can be used as a marker for clinical pregnancy. |
| Synonyms |
LIF; HILDA; MLPLI; CDF; DIA |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
